Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
about
Hostile takeovers: viral appropriation of the NF-kB pathwayA novel interferon regulatory factor (IRF), IRF-10, has a unique role in immune defense and is induced by the v-Rel oncoprotein.Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformationReticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survivalUnexpected functions of nuclear factor-κB during germinal center B-cell development: implications for lymphomagenesisTo be an ally or an adversary in bladder cancer: the NF-κB story has not unfoldedThe Rel/NF-kappaB signal transduction pathway: introductionThe c-Rel transcription factor and B-cell proliferation: a deal with the devilTargeting NF-kappaB in hematologic malignanciesNuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activityUpregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cellsTo NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate RegulatorOverexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profileControl of development and immunity by rel transcription factors in Drosophila.Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: transgenics and knockouts.Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: hijacking cellular IkappaB kinases.Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblastsCell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-kappaB oncogenesis.NF-κB, an active player in human cancers.Germinal center B cell maintenance and differentiation are controlled by distinct NF-κB transcription factor subunits.ERK and JNK activation is essential for oncogenic transformation by v-Rel.Differential regulation of the inhibitor of apoptosis ch-IAP1 by v-rel and the proto-oncogene c-rel.Absence of the steroid receptor coactivator-3 induces B-cell lymphoma.Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer.Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.NF-κB and cancer: a paradigm of Yin-Yang.The c-Rel Transcription Factor in Development and Disease.Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma.Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cellsNF-kappaB activation in development and progression of cancer.The NF-κB subunit c-Rel regulates Bach2 tumour suppressor expression in B-cell lymphomaNuclear factor-kB in thyroid carcinogenesis and progression: a novel therapeutic target for advanced thyroid cancer.Transcription factors as therapeutic targets in lymphoid malignancies.NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and AktInhibitory kappa B Kinases as targets for pharmacological regulation.The diverse and complex roles of NF-κB subunits in cancer.Promising personalized therapeutic options for diffuse large B-cell Lymphoma Subtypes with oncogene addictionsNovel NF-κB inhibitors: a patent review (2011 - 2014).NF-κB in cancer therapy.
P2860
Q22241900-0B5C8CAC-D77F-4D52-8DC5-FF7932AF36E6Q24537405-9F559E0C-30D0-4FE1-991D-8F70E905647AQ24537610-6256CA8A-6ADB-4F15-8B85-A0ABF139A836Q24647397-95020C31-7229-4704-A5DB-70EFCBD4A30EQ26822486-8D855A88-23A9-4ABC-A52D-13D4E2D68425Q28086858-626B7829-9143-4372-BA74-F88997BE2802Q28140718-E98790FE-3882-47B7-8DD0-20454C5A08B6Q28241767-CB69910D-D8F1-4C96-B439-756BFEDE735CQ28299055-E8B9AC62-934B-48E2-8FF4-29456C2F6461Q28383134-EA90853B-C1E2-4694-B221-35436FB95207Q28384366-DDF815AA-BEC2-4E62-8FB0-4FFA6D6AFADFQ28386593-BAEF6819-0DA5-4A74-895F-4ED3E0137A40Q33551720-ECFCFC62-D6E5-40E9-BE13-BF435BEE0AFCQ33797143-FDEE4468-4EB1-47EF-92A0-48D52259457CQ33797150-8FEDABC1-A278-4C31-8BEE-E5ECC3E97131Q33797174-1F5F2590-1643-491C-8808-4909AD9E9D5FQ34012219-AAE350A7-59DF-4081-8FBA-2A1F4802C0D7Q34101480-D618FC66-FC7D-47F4-885D-568C2328C5C3Q34138728-6BD82D91-DDFE-4D39-8F57-19A18070C5EBQ34230576-586E58A9-59BC-457B-8D84-F938EF7AB4B5Q34351185-CA585F31-8780-4D17-A7E6-514F164F690FQ34359416-565DE4FD-BD60-4743-BEE5-6810E5D78622Q34676664-DF05333E-83C0-411C-8CA4-27CADB8A4ACCQ35058278-6A32736C-814D-49C6-B8AF-B1D7A49404AAQ35169909-455B18EB-BC7E-45F5-8C5C-505EB02AA6E7Q35232248-01BCA6AE-4A66-4E25-AFFD-86F5CD15F560Q35556506-42817A65-518F-44E3-B945-63BD329E3042Q35990691-2EA6BA4F-1328-477D-B99E-64D1D711A2DBQ36369816-0C51E4F1-7FAE-441A-825C-58702D8E6D82Q36725293-E280A50B-1917-4D45-9D4C-0F6FB8952510Q36858771-9438A991-3A5F-4A0C-8F4A-4A12C9B853BCQ36949801-3AE3A3A9-433D-4CF4-8D42-51B4EB54ACABQ37008654-CA2E622D-FF54-464B-BC38-FC1F2490DD6CQ37286365-DD365BE7-255A-4461-A597-0D8D751C362AQ37399825-F91201A5-402B-46AF-9652-8EC82E89C309Q37907354-670B1DA4-2226-4CAD-80A2-157BDAA23780Q37976939-E0957852-BAA2-453D-A08D-4705CBB8087AQ38022591-512633E8-B5EF-4111-87B4-F484138432E2Q38305549-74CF39FC-E50C-4A54-82C7-BF2FD6703816Q38359190-D7D8A390-D738-4F94-BC13-60BF11E7B2B8
P2860
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
@ast
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
@en
type
label
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
@ast
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
@en
prefLabel
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
@ast
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
@en
P2860
P356
P1433
P1476
Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.
@en
P2093
Gilmore TD
P2860
P2888
P304
P356
10.1038/SJ.ONC.1203222
P407
P577
1999-11-01T00:00:00Z
P5875
P6179
1035605625